| GTC Biotherapeutics is the leader in the development, production, and commercialization of therapeutic proteins through transgenic animal technology. GTC has more than a dozen programs in development, including its internal proprietary products, one of which is in clinical trials. GTC has begun a clinical efficacy study in Europe with its lead internal program, recombinant human antithrombin III (rhATIII), a human blood plasma protein. |
